Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025

Briefs: Hikal and Sun Pharma

Sun Pharma gets 8 observations from USFDA for Halol facility

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis

Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%

Hikal invests Rs. 500 crore into fine chemicals plant at Panoli

Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base